Long-term lamivudine treatment for chronic hepatitis B in Japanese patients: A project of Kyushu University Liver Disease Study

Table 4 Forward stepwise logistic regression analysis for all independent factors contributing to virological breakthrough

Factors	Odds ratio	95% CI	P
(At baseline)
Cirrhosis	3.527	1.687 - 7.371	0.0008
HBeAg positivity	2.512	1.265 - 4.989	0.0085
Platelet counts less than 100 x 109/L	2.386	1.003 - 5.676	0.0491
(During treatment)
Decline of HBV-DNA less than 3.91	2.358	1.246 - 4.464	0.0084
within 6 mo of the start of treatment

HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; CI, confidence interval of odds ratios ¹Logarithmic transformed copies/mL.